Encouraging Patients to Ask Questions: Development and Pilot Testing of a Question Prompt List for Patients Undergoing a Biopsy for Suspected Prostate Cancer

Curr Oncol. 2023 Feb 8;30(2):2088-2104. doi: 10.3390/curroncol30020162.

Abstract

This study assessed the acceptability and feasibility of a question prompt list (QPL) to facilitate informed treatment decision-making in men with suspected localised prostate cancer, which involves values-based choices between options with similar efficacy but different side effects. The QPL was developed through iterative consultation with consumers, clinicians and researchers. Acceptability was assessed using study-specific questions regarding QPL satisfaction and usefulness and qualitative interviews. Feasibility was determined via the proportion of men given the QPL according to medical records and the completion of standardised measures of decisional outcomes. Quantitative data were analysed using descriptive and univariate statistics. Qualitative data were thematically analysed. Fifty-two men consented; 34 provided data for analysis. The QPL recipients reported moderate-high content satisfaction (70.6%) and perceived usefulness in guiding appointments when receiving biopsy results (64.7%). Two main qualitative themes also indicated the QPL acceptability: (1) the freedom to ask-acceptable timing, flexible usage and usefulness of the QPL, and (2) satisfaction with the QPL content. However, only 18.4% of eligible men received the QPL, indicating limited feasibility. The QPL is safe and acceptable, but further research is needed regarding how to facilitate the uptake of the question prompt list in clinical practice.

Keywords: prostate biopsy; prostate cancer; question prompt list; treatment decision-making.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Communication*
  • Humans
  • Male
  • Physician-Patient Relations
  • Prostatic Neoplasms*
  • Referral and Consultation
  • Surveys and Questionnaires

Grants and funding

This research was funded by The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), under the “Below the Belt Research Fund” grant. Allan ‘Ben’ Smith was supported by the Cancer Institute NSW (2021/CDF1138).